Next-generation sequencing (NGS) revealed ERBB2 amplification (CNV=3.50), a high tumor mutation burden (TMB 20.70Muts/Mb), and low microsatellite instability (MSI-L) status. This evidence concerns the gene ERBB2 and neoplasm.